Table 1.
Patient and tumor characteristics.
Fig 1.
Dosimetric characteristics of each third of the seminal vesicle, depending on the length of involved seminal vesicles on MRI.
Mean value (range) in Gy; Dx: dose delivered to x% of volume; PTV: planning target volume; CTV: clinical target volume; SV: seminal vesicle; SV PTV = SV CTV + 5 mm in all directions. Each SV was divided in three equal thirds, according to the cranio-spinal axis. The mean dose for each third of both SV is represented. The proximal third of the seminal vesicle is in orange, the second third is in green, and the distal third is in blue. The involved part of the seminal vesicle is in black.
Table 2.
Doses to the prostate and the seminal vesicles, depending on the length of seminal vesicle involvement on MRI.
Table 3.
Dosimetric characteristics of the rectum and the bladder according to the recommendations of the cooperative groups.
Fig 2.
Carcinological results for T3b prostate cancer patients.
(A)Results for biochemical and clinical recurrences and deaths. (B) Results for clinical recurrence detailed by local recurrence as the first event (local, pelvic lymph node, and metastasis). Clinical recurrence was defined as at least local or pelvic lymph node or metastasis recurrence.
Fig 3.
Impact of lymph node involvement (≤ 2 or ≥ 3 lymph nodes on MRI) on carcinological outcomes.
(A)on biochemical recurrence, (B) on clinical recurrence, (C) on death. Clinical recurrence was defined as at least local or pelvic lymph node or metastasis recurrence. The p value has been calculated from the logrank test.
Table 4.
Univariate analysis testing the impact of all parameters on all carcinological endpoints in the whole series.
Table 5.
Multivariate analysis testing the impact of all parameters on all carcinological endpoints in the whole series and for patients without lymph node involvement on MRI.
Table 6.
Univariate analysis testing the impact of all parameters on carcinological endpoints for patients without lymph node involvement on MRI.
Table 7.
Univariate analysis testing the impact of all parameters on grade ≥ 2 toxicity in the whole series.
Table 8.
Univariate analysis testing the impact of all parameters on grade ≥ 2 toxicity for patients without lymph node involvement on MRI.
Fig 4.
Impact of pelvic node dose on late digestive toxicity (grade ≥ 2).
The p value has been calculated from the logrank test.
Table 9.
Multivariate analysis testing the impact of all parameters on grade ≥ 2 toxicity in the whole series and for patients without lymph node involvement on MRI.
Table 10.
Review of the literature reporting treatment for T3b prostate cancer.